An information campaign on aminoglycosides use during septic shock failed to improve the quality of care

Annales Francaises d'Anesthesie et de Reanimation

Volumn 31, Issue 1, 2012, Pages

  Fischer, M O ^a,b   Parienti, J J ^a,b   Daurel, C ^a,b   Debruyne, D ^a,b   Verdon, R ^a,b   Gerard J L ^a,b   Hanouz, J L ^a,b   Fellahi, J L ^a,b  

^a CAEN UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE CAEN   (France)

Author keywords

Aminoglycosides; Pharmacological monitoring; Prescription; Septic shock

Indexed keywords

AMINOGLYCOSIDE;

ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG INFORMATION; DRUG MONITORING; DRUG USE; HEALTH CARE QUALITY; HEALTH PROGRAM; HUMAN; INTENSIVE CARE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MEDICAL PRACTICE; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRESCRIPTION; PROSPECTIVE STUDY; SEPTIC SHOCK;

AGED; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; COHORT STUDIES; DRUG MONITORING; DRUG PRESCRIPTIONS; ENDPOINT DETERMINATION; FEMALE; HOSPITAL MORTALITY; HOSPITALS, TEACHING; HUMANS; INFORMATION DISSEMINATION; INTENSIVE CARE; INTENSIVE CARE UNITS; LENGTH OF STAY; MALE; MIDDLE AGED; PATIENT CARE MANAGEMENT; PROSPECTIVE STUDIES; QUALITY IMPROVEMENT; SAMPLE SIZE; SHOCK, SEPTIC; TREATMENT OUTCOME;

EID: 84855870013     PISSN: 07507658     EISSN: 17696623     Source Type: Journal    
DOI: 10.1016/j.annfar.2011.08.021     Document Type: Article

References (19)

1. Annane D., Aegerter P., Jars-Guincestre M.C., Guidet B. Current epidemiology of septic shock: the CUB-Réa Network. Am J Respir Crit Care Med 2003, 168:165-172.
2. Dellinger R.P., Levy M.M., Carlet J.M., Bion J., Parker M.M., Jaeschke R., et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008, 36:296-327.
3. Kumar A., Roberts D., Wood K.E., Light B., Parrillo J.E., Sharma S., et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34:1589-1596.
4. Cometta A., Baumgartner J.D., Lew D., Zimmerli W., Pittet D., Chopart P., et al. Prospective randomized comparaison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in non neutropenic patients. Antimicrob Agents Chemother 1994, 38:1309-1313.
5. Dupont H., Carbon C., Carlet J. Monotherapy with a broad-spectrum beta-lactam is as effective as its combination with an aminoglycoside in treatment of severe generalyzed peritonitis: a multicenter randomized controlled trial. Antimicrob Agents Chemother 2000, 44:2028-2033.
6. Société française d'anesthésie et de réanimation Antibiothérapie probabiliste des états septiques graves. Ann Fr Anesth Reanim 2004, 23:1020-1026.
7. Micek S.T., Welch E.C., Khan J., Pervez M., Doherty J.A., Reichley R.M., et al. Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis. Antimicrob Agents Chemother 2010, 54:1742-1748.
8. Moore R.D., Smith R.S., Lietman P.S. Association of aminoglycoside plasma levels with therapeutic outcome in Gram negative pneumonia. Am J Med 1984, 77:657-662.
9. Moore R.D., Lietman P.S., Smith R.S. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987, 155:93-99.
10. Kashuba A.D., Nafzinger A.N., Drusano G.L., Bertino J.B. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by Gram-negative bacteria. Antimicrob Agents Chemother 1999, 43:623-629.
11. Zahar J.R., Rioux C., Girou E., Hulin A., Sauve C., Bernier-Combes A., et al. Inappropriate prescribing of aminoglycosides: risk factors and impact of an antibiotic control team. J Antimicrob Chemother 2006, 58:651-656.
12. Levy M.M., Fink M.P., Marshall J.C., Abraham E., Angus D., Cook D., et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 2003, 29:530-538.
13. Leong C.L., Buising K., Richards M., Robertson M., Street A. Providing guidelines and education is not enough: an audit of gentamicin use at The Royal Melbourne Hospital. Intern Med J 2006, 36:37-42.
14. Cleary P.D. Changing clinician behavior: necessary path to improvement or impossible dream?. Ann Intern Med 1999, 131:859-860.
15. Davis D., O'Brien M.A., Freemantle N., Wolf F.M., Mazmanian P., Taylor-Vaisey A. Impact of formal continuing medical education: do conferences, workshops, rounds, and other traditional continuing education activities change physician behavior or health care outcomes?. JAMA 1999, 282:867-874.
16. Daikos G.L., Lolans V.T., Jackson G.G. Fisrt-exposure adaptative resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use. Antimicrob Agents Chemother 1991, 35:117-123.
17. Karlowsky J.A., Zahnel G.G., Davidson R.J., Hoban D.J. Postantibiotic effect in Pseudomonas aeruginosa following single and multiple aminoglycoside exposures in vitro. J Antimicrob Chemother 1994, 33:937-947.
18. Agence française de sécurité sanitaire des produits de santé, Société de pathologie infectieuse de langue française, Groupe de pathologie infectieuse pédiatrique. Mise au point sur le bon usage des aminosides administrés par voie injectable: gentamicine, tobramycine, nétilmicine, amikacine. Propriétés pharmacologiques, indications, posologies et mode d'administration, surveillance du traitement. Mars 2011. http://www.afssaps.fr/content/download/32759/429534/version/2/file/MAP_Aminosides_Argumentaire.pdf.
19. Woolf S.H., Grol R., Hutchinson A., Eccles M., Grimshaw J. Potential benefits, limitations, and harms of clinical guidelines. BMJ 1999, 318:527-530.